tert-butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate | 612532-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[amino(phenyl)methyl]piperidine-1-carboxylate
• CAS: 612532-09-9
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: WTARUKRBKMNNAD-UHFFFAOYSA-N

物化性质

• 沸点：
  401.5±18.0 °C(Predicted)
• 密度：
  1.085±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 2,4-Dichloro-N-[phenyl[1-(propylsulfonyl)-4-piperidinyl]methyl]benzamide
  参考文献：
  名称：

  Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres

  摘要：

  This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach, in lieu of an HTS campaign, which provided intellectual property position. Members within this new [3.3.0]-based series displayed excellent GlyT1 potency, selectivity, free fraction, and modest CNS penetration. Moreover, enantioselective GlyT1 inhibition was observed, within this novel series and a number of other piperidine bioisosteric cores. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.011
• 作为产物：
  描述：

  1-Boc-4-[甲氧基(甲基)氨基甲酰]哌嗪 在 ammonium acetate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 16.17h， 生成 tert-butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS
  [FR] COMPOSÉS CARBOXAMIDES ISOXAZOLES

  摘要：

  本公开提供具有式（I）的替代异噁唑羧酰胺化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、A、X和Z如规范中所述。本公开还涉及使用式I的化合物治疗对SMYD蛋白的阻断具有响应的疾病，如SMYD3或SMYD2。本公开的化合物特别适用于治疗癌症。

  公开号：

  WO2016040498A1

文献信息

• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2011123937A1

  公开（公告）日：2011-10-13

  The present teachings provide a compound represented by Strutural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

  本教学提供了一种由结构式(I)表示的化合物，或其药用可接受的盐。还描述了一种药物组合物及其使用方法。
• [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS CARBOXAMIDES ISOXAZOLES
  申请人：EPIZYME INC

  公开号：WO2016040498A1

  公开（公告）日：2016-03-17

  The present disclosure provides substituted isoxazole carboxamide compounds having Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供具有式（I）的替代异噁唑羧酰胺化合物及其药用可接受的盐和溶剂化合物，其中R1、R2、A、X和Z如规范中所述。本公开还涉及使用式I的化合物治疗对SMYD蛋白的阻断具有响应的疾病，如SMYD3或SMYD2。本公开的化合物特别适用于治疗癌症。
• Identification of 4-(4-Aminopiperidin-1-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration
  作者：John J. Caldwell、Thomas G. Davies、Alastair Donald、Tatiana McHardy、Martin G. Rowlands、G. Wynne Aherne、Lisa K. Hunter、Kevin Taylor、Ruth Ruddle、Florence I. Raynaud、Marcel Verdonk、Paul Workman、Michelle D. Garrett、Ian Collins

  DOI：10.1021/jm701437d

  日期：2008.4.1

  inhibitor-PKA-PKB chimera complexes efficiently guided improvements in the potency and selectivity of the compounds, resulting in the identification of nanomolar 6-(piperidin-1-yl)purine, 4-(piperidin-1-yl)-7-azaindole, and 4-(piperidin-1-yl)pyrrolo[2,3- d]pyrimidine inhibitors of PKBbeta with antiproliferative activity and showing pathway inhibition in cells. A divergence in the binding mode was seen

  基于片段的筛选确定7-氮杂吲哚为蛋白激酶B抑制剂支架。使用抑制剂-PKA-PKB嵌合体复合物的反复结晶学方法对片段进行精细加工，可有效指导化合物效力和选择性的提高，从而鉴定出纳摩尔级的6-（哌啶-1-基）嘌呤，4-（哌啶-1-基）纳摩尔。 ）-7-氮杂吲哚和PKBbeta的4-（哌啶-1-基）吡咯并[2,3-d]嘧啶抑制剂具有抗增殖活性，并在细胞中表现出途径抑制作用。在包含4-氨基甲基哌啶和含4-氨基哌啶的分子之间观察到结合模式的差异。用4-氨基哌啶衍生物观察到PKB对PKA的选择性，大多数PKB选择性抑制剂（30倍）显示出PKA和PKA-PKB嵌合体之间的结合构象显着不同。
• SULFONYL-PIPERIDIN-4-YL METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS
  申请人：Lindsley Craig W.

  公开号：US20100256186A1

  公开（公告）日：2010-10-07

  In one aspect, the invention relates to compounds which are useful as inhibitors of glycine type 1 transporter (GlyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with glycine type 1 transporter (GlyT1) activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及一种化合物，可用作甘氨酸类型1转运体（GlyT1）活性的抑制剂；制备该化合物的合成方法；包含该化合物的制药组合物；以及使用该化合物和组合物治疗与甘氨酸类型1转运体（GlyT1）活性相关的疾病的方法。本摘要旨在作为搜索特定技术领域的扫描工具，不限制本发明。
• Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
  申请人：Page Naxos Patrick

  公开号：US20050215605A1

  公开（公告）日：2005-09-29

  The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 1 -C 6 Alkyl cycloalkyl, C 1 -C 6 -alkyl heteroaryl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocycloalkyl, said cycloalkyl or aryl or hetetoaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R 1 is selected from the group consisting of aryl, heteroaryl, C 3 -C 8 -cycloalkyl or -heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R 2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C 1 -C 5 -alkyl carboxy, C 1 -C 5 -alkyl acyl, C 1 -C 5 -alkyl alkoxycarbonyl, C 1 -C 5 -alkyl aminocarbonyl, C 1 -C 5 -alkyl acyloxy, C 1 -C 5 -alkyl acylamino, C 1 -C 5 -alkyl ureido, C 1 -C 5 alkyl amino, C 1 -C 5 -alkyl alkoxy, C 1 -C 5 -alkyl sulfanyl, C 1 -C 5 -alkyl sulfinyl, C 1 -C 5 -alkyl sulfonyl, C 1 -C 5 -alkyl sulfonylamino, C 1 -C 5 -alkyl sulfonyloxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl, heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 2 -C 6 -alkyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, or C 2 -C 6 -alkynyl heteroaryl.

  本发明涉及式（II）的噻唑烷羧酰胺衍生物，用于治疗和/或预防早产、早产、痛经以及在剖腹产前停止分娩。其中，G选择自C1-C6烷基芳基，C1-C6烷基杂芳基，C1-C6烷基环烷基，C1-C6烷基杂环烷基，芳基，杂芳基，C3-C8环烷基或-杂环烷基，所述环烷基或芳基或杂芳基基团可以与环烷基或芳基或杂芳基基团融合。R1选择自芳基，杂芳基，C3-C8环烷基或-杂环烷基，所述（杂）环烷基或芳基或杂芳基基团可以与（杂）环烷基或芳基或杂芳基基团融合。R2选择自H，羧基，酰基，烷氧羰基，氨基羰基，C1-C5烷基羧基，C1-C5烷基酰基，C1-C5烷基烷氧羰基，C1-C5烷基氨基羰基，C1-C5烷基酰氧基，C1-C5烷基酰胺基，C1-C5烷基脲基，C1-C5烷基氨基，C1-C5烷基烷氧基，C1-C5烷基硫醇基，C1-C5烷基亚砜基，C1-C5烷基磺酰基，C1-C5烷基磺酰胺基，C1-C5烷基磺酰氧基，C1-C6烷基，C2-C6烯基，C2-C6炔基，芳基，杂芳基，C3-C8环烷基，杂环烷基，C1-C6烷基芳基，C2-C6烷基杂芳基，C1-C6烷基环烷基，C1-C6烷基杂环烷基，C2-C6烯基芳基，C2-C6烯基杂芳基，C2-C6炔基芳基或C2-C6炔基杂芳基。